21-Gene recurrence scores

The 21-Gene Recurrence Score Assay

Between 2001–2003 Paik and others, from a US-based multiinstitutional clinical trials group (the NSABP) that includes many Canadian centres, developed an assay to identify 21 genes from tumour samples that collectively significantly predicted patients’ outcomes (recurrences, breast cancer deaths, and response to chemotherapy).1 The 21-gene assay was based on advances in genetic techniques, refi...

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

PURPOSE To evaluate the 21-gene recurrence score (RS) on decision-making in a population-based cohort. PATIENTS AND METHODS Patients with axillary node-negative or nodal micrometastases, estrogen receptor-positive, and human epidermal growth factor receptor 2-negative breast cancer being considered for chemotherapy were eligible. All cancer treatment centers in Ontario, Canada, participated. ...

Clinical scores to predict recurrence risk of venous thromboembolism.

Venous thromboembolism (VTE) is a common and chronic disease with a considerable risk of recurrence. Patients with unprovoked (in the absence of a transient risk factor) VTE have a recurrence risk as high as 30% within five years after cessation of anticoagulation. Depending on patient selection the case-fatality rate of recurrence ranges between 3.6%-10%. Thus, indefinite anticoagulation treat...

Genetic Risk Scores Predict Recurrence of Acute Coronary Syndrome

Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts).

13 Background: Genomic assays are increasingly incorporated into treatment planning for pts with early stage BC to provide prognostic and/or predictive information. MP is a validated predictor of recurrence risk (RR) in pts without any treatment and RS is a validated predictor of RR in pts treated with 5 years of hormonal therapy (HT). Because concordance between RS and MP is largely unknown, w...